AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

Chronic inflammation is a fundamental process implicated in the pathogenesis and progression of various complex immune ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

The stock's fall snapped a three-day winning streak.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $180 which represents a slight increase of $1.61 or 0.90% from the prior close of $178.39. The stock opened at $178.41 and touched a low ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of ...

Schwab and Vanguard are both giants in the investment arena. Retirees who are considering between the two should base ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...